{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:06:44Z","timestamp":1785240404401,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:29:26Z","timestamp":1778023766000},"page":"e969-e977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0657-1328","authenticated-orcid":false,"given":"Alexander M.","family":"Gorzewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8715-3207","authenticated-orcid":false,"given":"Christina","family":"Raker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7431-3771","authenticated-orcid":false,"given":"Victoria A.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-3550","authenticated-orcid":false,"given":"Thomas","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0426-2948","authenticated-orcid":false,"given":"Sai P.","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari R.","family":"Pelcovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2026.05.001_bib0001","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.001_bib0002","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/hematolrep16010006","article-title":"Survival outcomes of patients with mantle cell lymphoma: a retrospective, 15-year, real-life study","volume":"16","author":"Cencini","year":"2024","journal-title":"Hematol Rep"},{"issue":"6","key":"10.1016\/j.clml.2026.05.001_bib0003","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"32","key":"10.1016\/j.clml.2026.05.001_bib0004","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-free survival should not be used as a primary end point for registration of anticancer drugs","volume":"41","author":"Booth","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.05.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clml.2026.05.001_bib0006","article-title":"A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"10.1016\/j.clml.2026.05.001_bib0007","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1208\/s12248-017-0056-x","article-title":"Assessment of correlation between early and late efficacy endpoints to identify potential surrogacy relationships in non-Hodgkin lymphoma: a literature-based meta-analysis of 108 phase II and phase III studies","volume":"19","author":"Zhu","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.clml.2026.05.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2025.100699","article-title":"Progression-free survival is strongly associated with overall survival in relapsed\/refractory diffuse large B-cell lymphoma in the CAR T-cell era","volume":"47","author":"Gorzewski","year":"2026","journal-title":"J Cancer Policy"},{"issue":"3","key":"10.1016\/j.clml.2026.05.001_bib0009","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pst.207","article-title":"Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation","volume":"5","author":"Burzykowski","year":"2006","journal-title":"Pharm Stat"},{"issue":"4","key":"10.1016\/j.clml.2026.05.001_bib0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jval.2025.01.005","article-title":"A comparison of the performance of 6 surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis","volume":"28","author":"Vickers","year":"2025","journal-title":"Value Health"},{"issue":"10441","key":"10.1016\/j.clml.2026.05.001_bib0011","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clml.2026.05.001_bib0012","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.05.001_bib0013","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.001_bib0014","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.23.01586","article-title":"Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: a LYSA study","volume":"42","author":"Sarkozy","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.05.001_bib0015","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41375-024-02254-2","article-title":"The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma\u2014a randomized, open-label phase III trial of the European mantle cell lymphoma network","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.clml.2026.05.001_bib0016","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.clml.2026.05.001_bib0017","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European mantle cell lymphoma network","volume":"41","author":"Hermine","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.001_bib0018","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.05.001_bib0019","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.001_bib0020","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.clml.2026.05.001_bib0021","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.05.001_sbref0022","series-title":"66th American Society of Hematology Annual Meeting and Expositions","author":"Fenske","year":"2024"},{"issue":"10","key":"10.1016\/j.clml.2026.05.001_bib0023","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.05.001_bib0024","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2015.128710","article-title":"The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial","volume":"101","author":"Rule","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2026.05.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70102","article-title":"Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients","volume":"9","author":"Tavarozzi","year":"2025","journal-title":"Hemasphere"},{"issue":"10514","key":"10.1016\/j.clml.2026.05.001_bib0026","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","article-title":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial","volume":"406","author":"Lewis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.05.001_bib0027","article-title":"FDA approves ibrutinib for mantle cell lymphoma","author":"Inman","year":"2013","journal-title":"OncLive"},{"issue":"3","key":"10.1016\/j.clml.2026.05.001_bib0028","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejca.2011.10.028","article-title":"Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?","volume":"48","author":"Amir","year":"2012","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clml.2026.05.001_bib0029","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.24.01192","article-title":"End point surrogacy in first-line chronic lymphocytic leukemia","volume":"43","author":"Simon","year":"2025","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.clml.2026.05.001_bib0030","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/bjh.19449","article-title":"Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: a systematic review and meta-analysis","volume":"204","author":"Milrod","year":"2024","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.clml.2026.05.001_bib0031","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","article-title":"Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient\u2013level analysis of multiple randomized trials (SEAL)","volume":"36","author":"Shi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.05.001_bib0032","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.clml.2026.05.001_bib0033","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.23.00225","article-title":"Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival","volume":"41","author":"Merino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.05.001_bib0034","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/19466315.2024.2365648","article-title":"Monitoring overall survival in pivotal trials in indolent cancers","volume":"17","author":"Fleming","year":"2025","journal-title":"Stat Biopharm Res"},{"issue":"11","key":"10.1016\/j.clml.2026.05.001_bib0035","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2026.05.001_bib0036","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.05.001_bib0037","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ajh.27582","article-title":"Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials","volume":"100","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.001_bib0038","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bjh.15805","article-title":"Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population","volume":"185","author":"Magnano","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.001_bib0039","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41408-025-01241-9","article-title":"Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study","volume":"15","author":"Sarkozy","year":"2025","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2026.05.001_bib0040","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.2023022354","article-title":"High-risk MCL: recognition and treatment","volume":"145","author":"Jain","year":"2025","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2026.05.001_bib0041","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.05.001_bib0042","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.05.001_bib0043","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/10428194.2017.1361032","article-title":"Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility","volume":"59","author":"Guidot","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2026.05.001_bib0044","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clml.2016.01.001","article-title":"Differences in quality of life between bendamustine-rituximab and R-CHOP\/R-CVP in patients with previously untreated advanced indolent non-Hodgkin lymphoma or mantle cell lymphoma","volume":"16","author":"Burke","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clml.2026.05.001_bib0045","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1186\/s12885-025-14724-6","article-title":"Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data","volume":"25","author":"Kort\u00fcm","year":"2025","journal-title":"BMC Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.001_bib0046","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2024-200735","article-title":"Role of autologous stem cell transplantation in the context of Ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network","volume":"144","author":"Dreyling","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:57:36Z","timestamp":1785239856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001448"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}